177 related articles for article (PubMed ID: 37587335)
1. Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC; Campbell NK; Mangan NE; Vandenberg CJ; Gearing LJ; Matthews AY; Gould JA; Tate MD; Wray-McCann G; Ying L; Rosli S; Brockwell N; Parker BS; Lim SS; Bilandzic M; Christie EL; Stephens AN; de Geus E; Wakefield MJ; Ho GY; McNally O; ; McNeish IA; Bowtell DDL; de Weerd NA; Scott CL; Bourke NM; Hertzog PJ
Nature; 2023 Aug; 620(7976):1063-1070. PubMed ID: 37587335
[TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
3. Interferon epsilon and ovarian cancer.
Elorbany S; Malacrida B; Balkwill F
Trends Cancer; 2023 Dec; 9(12):985-986. PubMed ID: 37778961
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
5. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
[TBL] [Abstract][Full Text] [Related]
6. Interferon ε restricts Zika virus infection in the female reproductive tract.
Xu C; Wang A; Ebraham L; Sullivan L; Tasker C; Pizutelli V; Couret J; Hernandez C; Deb PQ; Fritzky L; Subbian S; Gao N; Lo Y; Salvatore M; Rivera A; Lemenze A; Fitzgerald-Bocarsly P; Tyagi S; Lu W; Beaulieu A; Chang TL
bioRxiv; 2023 Apr; ():. PubMed ID: 37066223
[TBL] [Abstract][Full Text] [Related]
7. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
[TBL] [Abstract][Full Text] [Related]
9. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract][Full Text] [Related]
10. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
11. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.
Jazaeri AA; Bryant JL; Park H; Li H; Dahiya N; Stoler MH; Ferriss JS; Dutta A
Neoplasia; 2011 Oct; 13(10):899-911. PubMed ID: 22028616
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
[TBL] [Abstract][Full Text] [Related]
13. [Management of hereditary ovarian cancer].
Joó JG; Ládi S; Nagy BZ; Langmár Z
Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
[TBL] [Abstract][Full Text] [Related]
14. Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
Feng L; Yang W; Zhao H; Bakkum-Gamez J; Sherman ME; Kannan N
Methods Mol Biol; 2022; 2429():445-454. PubMed ID: 35507180
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
Hollingsworth J; Lau A; Tone A; Kollara A; Allen L; Colgan TJ; Dube V; Rosen B; Murphy KJ; Greenblatt EM; Feigenberg T; Virtanen C; Brown TJ
Neoplasia; 2018 Jul; 20(7):697-709. PubMed ID: 29852322
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Karst AM; Jones PM; Vena N; Ligon AH; Liu JF; Hirsch MS; Etemadmoghadam D; Bowtell DD; Drapkin R
Cancer Res; 2014 Feb; 74(4):1141-52. PubMed ID: 24366882
[TBL] [Abstract][Full Text] [Related]
17. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
Folkins AK; Jarboe EA; Saleemuddin A; Lee Y; Callahan MJ; Drapkin R; Garber JE; Muto MG; Tworoger S; Crum CP
Gynecol Oncol; 2008 May; 109(2):168-73. PubMed ID: 18342932
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
[TBL] [Abstract][Full Text] [Related]
20. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
